Lung cancer is the leading cause of cancer death in developed countries. However, in the last few years we observed an important acceleration in drug development due to oncogenic driver tumors discovery. Sharing and putting together preclinical data from benchmark and data from clinical research is the scientific paradigm that allows real breakthrough in clinical practice in this field, but only a few targeted agents are worthy and practice changing. The clinical research and proper use of statistical methodology are the pillars to continue to achieve important goals like improvement of overall survival. A good medical oncologist should be able to critically read a scientific paper and move from the observed outcomes into clinical perspective. Despite clinical improvements, sometimes the union of promising targeted agents and optimistic expectations misrepresent the reality and the value of clinical research. In this article, we try to analyze the meaning of statistical assumptions from clinical trials, especially in lung cancer, through a critical review of the concept of value-based medicine. We also attempt to give the reader some practical tools to weigh scientific value of literature reports.

Cortinovis, D., Abbate, M., Bidoli, P., Pelizzoni, D., Canova, S. (2015). Interpretation of lung cancer study outcomes. JOURNAL OF THORACIC DISEASE, 7(11), E541-E547 [10.3978/j.issn.2072-1439.2015.11.26].

Interpretation of lung cancer study outcomes

Cortinovis D
;
Bidoli P;
2015

Abstract

Lung cancer is the leading cause of cancer death in developed countries. However, in the last few years we observed an important acceleration in drug development due to oncogenic driver tumors discovery. Sharing and putting together preclinical data from benchmark and data from clinical research is the scientific paradigm that allows real breakthrough in clinical practice in this field, but only a few targeted agents are worthy and practice changing. The clinical research and proper use of statistical methodology are the pillars to continue to achieve important goals like improvement of overall survival. A good medical oncologist should be able to critically read a scientific paper and move from the observed outcomes into clinical perspective. Despite clinical improvements, sometimes the union of promising targeted agents and optimistic expectations misrepresent the reality and the value of clinical research. In this article, we try to analyze the meaning of statistical assumptions from clinical trials, especially in lung cancer, through a critical review of the concept of value-based medicine. We also attempt to give the reader some practical tools to weigh scientific value of literature reports.
Articolo in rivista - Articolo scientifico
Lung cancer
English
2015
7
11
E541
E547
reserved
Cortinovis, D., Abbate, M., Bidoli, P., Pelizzoni, D., Canova, S. (2015). Interpretation of lung cancer study outcomes. JOURNAL OF THORACIC DISEASE, 7(11), E541-E547 [10.3978/j.issn.2072-1439.2015.11.26].
File in questo prodotto:
File Dimensione Formato  
Interpretation of lung cancer study outcomes.pdf

Solo gestori archivio

Dimensione 190.88 kB
Formato Adobe PDF
190.88 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/260671
Citazioni
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 2
Social impact